
1. bmc res notes. 2018 apr 2;11(1):215. doi: 10.1186/s13104-018-3296-7.

cross sectional study prevalence sickle cell alleles c among patients
with mild malaria ivory coast.

tossea sk(1), adji eg(1), coulibaly b(1), ako ba(1), coulibaly dn(1), joly
p(2)(3), assi sb(4), toure a(1), jambou r(5)(6).

author information: 
(1)departement de parasitologie mycologie, institut pasteur de côte d'ivoire, bp 
490, abidjan 01, côte d'ivoire.
(2)univ lyon, university claude bernard lyon 1, ea 7424, lyon, france.
(3)unité de pathologie moléculaire du globule rouge, laboratoire de biochimie et 
biologie moléculaire grand est, hôpital edouard herriot, hospices civils de lyon,
lyon, france.
(4)programme national de lutte contre le paludisme, ministère de la santé,
abidjan, côte d'ivoire.
(5)departement de parasitologie mycologie, institut pasteur de côte d'ivoire, bp 
490, abidjan 01, côte d'ivoire. rjambou@pasteur.fr.
(6)departement parasites et insectes vecteurs, institut pasteur paris, paris,
france. rjambou@pasteur.fr.

objectives: sickle cell anemia due mutations betaglobin gene,
inducing abnormal hemoglobin. west africa main mutations lead c
types hemoglobin. patients homozygote mutations seem protected against
severe malaria, mild disease. prevalence abnormal
hemoglobin among patients attending dispensaries mild malaria thus
unknown. retrospective study conducted update data prevalence 
s c hemoglobin among patients attending dispensaries mild malaria.
enrolment patients conducted vivo malaria treatment efficacy
survey following 42 days protocol. group non-infected pregnant women
and group patients fever different malaria, also recruited in
the dispensaries.
results: 794 blood samples included. c genotypes found the
regions ivory coast highest prevalence northern region (s 
c genotypes, 27%). non-infected patients, prevalence mutations higher
than malaria patients.
conclusion: high proportion patients mild malaria carried genetic
hemoglobin disorder. population high risk must better investigated 
control treatment efficacy manage complications.

doi: 10.1186/s13104-018-3296-7 
pmcid: pmc5880027
pmid: 29609623  [indexed medline]

